4.22
—
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Lasa Supergenerics
Its shares trade on NSE under the ticker LASA.NS. It has been listed since 21 September 2017. In the fiscal year to 31 March 2026, it reported revenue of ₹251.4m and a net loss of ₹340.9m. At that date it held total assets of ₹665.7m and shareholders' equity of ₹496.2m.
Lasa Supergenerics Ltd. engages in the manufacture of veterinary preparations. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-09-21. The firm is engaged in the business of manufacturing, trading, producing, processing, preparing, treating chemicals, API, pharmaceuticals, drugs and others. The company specializes in catalyst chemistry and manufactures anthelmintic/veterinary API products. The firm's products include API products, other API products, animal feed ingredients and reagents for therapeutic use. Its API products include Albendazole, Fenbendazole, Oxfendazole, Providone Iodine, Nitroxylene, Ricobendazole, Halquinol and others. Its animal feed ingredients include potassium iodide, cobalt sulfate, sodium selenate, ethylediamine dihydroiodide and vanadyl sulfate. Its reagents for therapeutic use include cetylpyridinium chloride, bismuth subsalicylate and sodium selenite. The firm's manufacturing facility is located at Mahad and Chiplun, Maharashtra.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Sept 2017
- Employees
- 89
- Website
- lasalabs.com ↗
Leadership
Pay as last reported
- Dr. Omkar HerlekarChairman of the Board, Managing Director₹2.2m
- Mrs. Varsha JoshiChief Financial Officer
- Mr. Shivanand HegdeWhole-time Director₹1.5m
- Mr. Umesh PawarWhole-Time Director, since 2025
- Mr. Pravin LachakeNon-Executive Independent Director
- Mr. Ketan SongalNon-Executive Independent Director
- Mr. Yogesh UghadaNon-Executive Independent Director
- Mrs. Rekha WakhNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Lasa Supergenerics Ltd specializes in veterinary API products like Albendazole and Fenbendazole.
- The company manufactures anthelmintic/veterinary API products at Mahad and Chiplun facilities.
- Lasa Supergenerics employs 89 full-time staff in the pharmaceuticals sector.
Weaknesses
- The company has a small workforce of 89 employees in the pharmaceuticals industry.
- Lasa Supergenerics Ltd lacks diversification beyond veterinary pharmaceuticals.
- The firm's manufacturing is limited to Mahad and Chiplun locations in Maharashtra.
Opportunities
- Expanding API product lines to include more veterinary drugs like Oxfendazole.
- Increasing market share in the Indian veterinary pharmaceuticals sector.
- Growing demand for animal feed ingredients such as potassium iodide in India.
Threats
- Competition from larger pharmaceutical firms in the Indian market.
- Regulatory changes affecting veterinary drug manufacturing in India.
- Supply chain disruptions impacting API production in Maharashtra.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.